1. Home
  2. VYGR vs DNMX Comparison

VYGR vs DNMX Comparison

Compare VYGR & DNMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$4.02

Market Cap

226.8M

Sector

Health Care

ML Signal

HOLD

DNMX

Dynamix Corporation III Class A Ordinary Shares

N/A

Current Price

$9.89

Market Cap

265.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
VYGR
DNMX
Founded
2013
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
226.8M
265.4M
IPO Year
2015
2025

Fundamental Metrics

Financial Performance
Metric
VYGR
DNMX
Price
$4.02
$9.89
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$17.00
N/A
AVG Volume (30 Days)
375.7K
126.7K
Earning Date
11-10-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,316,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$71.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.65
$9.87
52 Week High
$5.96
$9.96

Technical Indicators

Market Signals
Indicator
VYGR
DNMX
Relative Strength Index (RSI) 46.28 N/A
Support Level $3.89 N/A
Resistance Level $4.19 N/A
Average True Range (ATR) 0.19 0.00
MACD 0.00 0.00
Stochastic Oscillator 50.57 0.00

Price Performance

Historical Comparison
VYGR
DNMX

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About DNMX Dynamix Corporation III Class A Ordinary Shares

Dynamix Corp III is a a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: